Aldosteronoma (Primary Hyperaldosteronism)

Aldosteronoma, also known as primary hyperaldosteronism (PHA) or Conn's syndrome, is an adrenocortical neoplasm, typically a benign adenoma, that autonomously secretes excessive aldosterone. This results in a clinical syndrome characterized by systemic arterial hypertension, hypokalemia, and metabolic alkalosis. In veterinary medicine, aldosteronomas are most commonly diagnosed in ferrets and cats, with rare reports in dogs. The tumor arises from the zona glomerulosa of the adrenal cortex, leading to unregulated mineralocorticoid excess. The condition is distinct from secondary hyperaldosteronism, which is a physiological response to activation of the renin-angiotensin-aldosterone system (RAAS) due to renal hypoperfusion or hepatic disease. Aldosteronoma is a progressive disorder that can cause significant morbidity and mortality if left untreated, primarily due to the cardiovascular and renal consequences of chronic hypertension and hypokalemia.

The exact etiology of aldosteronoma is not fully understood, but several mechanisms have been proposed. In ferrets, there is a strong association with hyperadrenocorticism, and aldosterone-secreting tumors often arise in the context of adrenal cortical hyperplasia or neoplasia. In cats, the majority of aldosteronomas are benign adenomas, but malignant carcinomas have been reported. Genetic mutations, such as those in the KCNJ5, ATP1A1, ATP2B3, CACNA1D, and CTNNB1 genes, have been identified in human aldosteronomas and may play a role in veterinary cases, although specific mutations have not been extensively characterized in animals. Chronic stimulation of the adrenal cortex by trophic hormones, such as ACTH, or local growth factors may contribute to tumorigenesis. Additionally, chronic hypokalemia itself can induce adrenal cortical changes, potentially creating a feedback loop. Environmental factors, such as exposure to endocrine-disrupting chemicals, have been hypothesized but not proven. In cats, no clear breed or sex predisposition has been identified, but the disease is more common in older animals, suggesting an age-related degenerative or neoplastic process.

Aldosteronoma is a rare endocrine disorder in dogs and cats but is relatively more common in ferrets. In cats, primary hyperaldosteronism is the most common cause of hyperaldosteronism, with a median age of onset around 11-13 years. No strong breed predisposition has been reported, but some studies suggest a higher incidence in domestic shorthair cats. In dogs, the condition is extremely rare, with only isolated case reports; it may occur in middle-aged to older dogs, with no breed predilection. Ferrets are uniquely predisposed to adrenal gland tumors, and aldosteronomas account for a significant proportion of these tumors, often occurring in neutered animals, typically between 3 and 7 years of age. The incidence in ferrets is high, with adrenal disease affecting up to 20% of pet ferrets in some regions. There is no known sex predilection in cats, but in ferrets, neutered males and females are equally affected. Geographic variation is not well-documented, but the disease is recognized worldwide.

Aldosterone is a mineralocorticoid hormone produced by the zona glomerulosa of the adrenal cortex. Its primary actions are mediated through the mineralocorticoid receptor (MR) in the distal nephron, where it increases sodium reabsorption and potassium and hydrogen ion excretion. In aldosteronoma, autonomous aldosterone secretion leads to excessive sodium and water retention, expansion of extracellular fluid volume, and suppression of renin secretion. The resulting hypertension is often severe and resistant to standard antihypertensive therapy. Hypokalemia occurs due to increased renal potassium wasting, which can cause muscle weakness, cardiac arrhythmias, and metabolic alkalosis. Chronic hypokalemia can lead to nephrogenic diabetes insipidus, causing polyuria and polydipsia. Additionally, aldosterone has direct profibrotic and proinflammatory effects on the heart, blood vessels, and kidneys, contributing to target organ damage independent of blood pressure. In cats, the clinical signs are often dominated by the effects of hypokalemia, such as cervical ventroflexion and muscle weakness, while hypertension may be an incidental finding. In ferrets, the disease may present with alopecia and other signs of hyperadrenocorticism due to concurrent sex hormone secretion.

Predisposing factors for aldosteronoma include advanced age, as the condition is most commonly diagnosed in older cats and ferrets. In ferrets, neutering is a significant risk factor for adrenal gland tumors, likely due to the loss of negative feedback on gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH), which can stimulate adrenal cortical cells. Chronic kidney disease, which is common in older cats, may predispose to secondary hyperaldosteronism, but primary aldosteronoma can also occur concurrently. Genetic factors are suspected, as certain breeds may have a higher incidence, although this is not well-established. Environmental factors, such as exposure to endocrine-disrupting chemicals, have been hypothesized but not proven. In cats, no specific dietary or management factors have been identified. Concurrent endocrine disorders, such as hyperthyroidism or diabetes mellitus, may complicate the clinical picture but are not direct predisposing factors.

Clinical signs of aldosteronoma are primarily related to hypokalemia and hypertension. In cats, the most common presenting signs include muscle weakness, particularly cervical ventroflexion (a classic sign of hypokalemia), lethargy, and polyuria/polydipsia. Ocular signs, such as retinal detachment or hemorrhage, may occur due to severe hypertension. Some cats may present with blindness. In ferrets, clinical signs often include bilateral symmetrical alopecia, pruritus, and vulvar enlargement in females, due to concurrent sex hormone secretion. Hypertension may cause neurological signs such as seizures or ataxia. In dogs, signs are similar to cats, with weakness, polyuria, polydipsia, and hypertension. Chronic hypokalemia can lead to muscle wasting and cardiac arrhythmias. In advanced cases, congestive heart failure may develop due to hypertensive cardiomyopathy. Physical examination may reveal a palpable abdominal mass if the tumor is large, although this is uncommon. Blood pressure measurement is essential, as hypertension is present in the majority of cases.

Differential diagnoses for aldosteronoma include: 1) Chronic kidney disease (CKD) with secondary hyperaldosteronism: CKD can cause hypertension and hypokalemia, but aldosterone levels are typically normal or elevated with high renin levels, whereas in aldosteronoma, renin is suppressed. 2) Hyperthyroidism in cats: Can cause hypertension and weight loss, but hypokalemia is uncommon, and thyroid hormone levels are elevated. 3) Diabetes mellitus: Can cause polyuria/polydipsia and weakness, but hyperglycemia and glucosuria are present. 4) Hypokalemic polymyopathy due to other causes, such as gastrointestinal potassium loss (e.g., chronic diarrhea) or renal tubular acidosis: These conditions have normal or low aldosterone levels. 5) Pheochromocytoma: Can cause hypertension, but clinical signs are more episodic, and catecholamine levels are elevated. 6) Pituitary-dependent hyperadrenocorticism (Cushing's disease): Can cause hypertension and muscle weakness, but cortisol levels are elevated, and skin changes are common. 7) Primary hyperparathyroidism: Can cause hypercalcemia, which may lead to weakness and polyuria, but aldosterone levels are normal. 8) Hepatic disease: Can cause hypertension and hypokalemia due to altered RAAS, but liver enzymes and bile acids are abnormal. 9) Essential hypertension: Rare in cats and dogs, and aldosterone levels are normal. 10) Hypoadrenocorticism (Addison's disease): Can cause weakness and electrolyte abnormalities, but typically hyperkalemia and hyponatremia are present, and aldosterone is low.

The diagnostic algorithm for aldosteronoma begins with a thorough history and physical examination, with particular attention to blood pressure measurement and neurological, ocular, and cardiovascular assessments. If hypertension and/or hypokalemia are identified, baseline laboratory tests, including serum biochemistry, urinalysis, and a complete blood count, should be performed. If hypokalemia is confirmed, a plasma aldosterone concentration (PAC) and plasma renin activity (PRA) should be measured. A PAC-to-PRA ratio (aldosterone-to-renin ratio, ARR) is the most reliable screening test. An ARR greater than 20-30 (with PAC in ng/dL and PRA in ng/mL/h) is highly suggestive of primary hyperaldosteronism. However, ARR can be affected by medications (e.g., ACE inhibitors, spironolactone) and concurrent diseases, so these should be considered. If the ARR is equivocal, a confirmatory test such as a saline suppression test or fludrocortisone suppression test may be performed, but these are rarely used in veterinary medicine. Imaging of the adrenal glands via abdominal ultrasound is essential to identify an adrenal mass. A unilateral adrenal mass in a patient with compatible clinical signs and elevated ARR is strongly supportive of aldosteronoma. Advanced imaging, such as CT or MRI, may be used for surgical planning. Histopathology of the excised adrenal gland is the gold standard for definitive diagnosis.

Laboratory findings in aldosteronoma include: 1) Serum biochemistry: Hypokalemia (typically <3.5 mEq/L in cats and dogs), hypernatremia (mild), and metabolic alkalosis (elevated bicarbonate). Creatinine and BUN may be normal or mildly elevated if concurrent renal disease is present. 2) Urinalysis: Isosthenuria (USG <1.030) due to impaired concentrating ability, and proteinuria may be present. 3) Complete blood count: Usually unremarkable, but stress leukogram may be present. 4) Blood gas analysis: Metabolic alkalosis with compensatory hypoventilation. 5) Endocrine assays: Elevated plasma aldosterone concentration (PAC) with suppressed plasma renin activity (PRA), resulting in an elevated aldosterone-to-renin ratio (ARR). In cats, PAC is typically >1000 pmol/L (or >36 ng/dL) with PRA <0.5 ng/mL/h. 6) Other biomarkers: NT-proBNP may be elevated if cardiac disease is present. 7) In ferrets, concurrent elevations in sex hormones (estradiol, androstenedione, 17-hydroxyprogesterone) may be seen due to adrenal cortical hyperplasia.

Imaging findings in aldosteronoma: 1) Abdominal ultrasonography: The most commonly used modality. It may reveal a unilateral adrenal mass, typically hypoechoic, with a distinct capsule. The mass may be small (0.5-2 cm in cats) and can be missed if not carefully evaluated. Doppler ultrasound can assess vascular invasion. 2) Computed Tomography (CT): Provides superior anatomical detail and is useful for surgical planning. CT can detect small masses and assess the contralateral adrenal gland. It can also identify metastasis in cases of malignant aldosteronoma. 3) Magnetic Resonance Imaging (MRI): Rarely used but can be helpful in differentiating adrenal masses from other retroperitoneal structures. 4) Thoracic radiography: May be indicated to evaluate for metastasis in cases of suspected malignancy, although aldosteronomas are usually benign. 5) Echocardiography: May be performed to assess hypertensive cardiomyopathy, which is a common complication of chronic hypertension.

Cytology and histopathology are essential for definitive diagnosis. Fine-needle aspiration (FNA) of the adrenal mass may be performed under ultrasound guidance, but it is not always diagnostic and carries a risk of hemorrhage. Cytology may show clusters of polygonal cells with abundant vacuolated cytoplasm, consistent with steroid-producing cells. Histopathology of the excised adrenal gland is the gold standard. Aldosteronomas are typically well-circumscribed, encapsulated masses composed of cells resembling the zona glomerulosa. They may show mild to moderate anisocytosis and anisokaryosis, but mitotic figures are rare. Malignant aldosteronomas (carcinomas) are characterized by capsular invasion, vascular invasion, and higher mitotic activity. Immunohistochemistry for aldosterone synthase (CYP11B2) can confirm the diagnosis, but this is not routinely available.

Treatment of aldosteronoma involves medical management and surgical excision. Medical management is aimed at controlling hypertension and hypokalemia. The primary medical therapy is the mineralocorticoid receptor antagonist spironolactone, which directly blocks aldosterone's effects. In cats, spironolactone is dosed at 1-2 mg/kg PO q12h. In dogs, the dose is 1-2 mg/kg PO q12h. In ferrets, 1-2 mg/kg PO q12h. Potassium supplementation is often necessary, using potassium gluconate or potassium citrate. The dose is titrated based on serum potassium levels. For hypertension, amlodipine (0.1-0.2 mg/kg PO q24h in cats and dogs) is the preferred antihypertensive agent. If blood pressure remains uncontrolled, additional agents such as ACE inhibitors (e.g., enalapril 0.5 mg/kg PO q12h) or beta-blockers may be added. Surgical adrenalectomy is the treatment of choice for unilateral aldosteronoma and is curative in most cases. Surgery should be performed after stabilization of blood pressure and potassium levels. In cats, adrenalectomy is associated with a good prognosis, with a median survival time of >3 years. In ferrets, surgery is also recommended, but medical management with melatonin or GnRH analogs may be used for non-surgical candidates. Postoperative management includes monitoring for hypoadrenocorticism, as the contralateral adrenal gland may be suppressed.

The prognosis for aldosteronoma is generally good with appropriate treatment. In cats, surgical excision of a benign adenoma is curative, with a median survival time of 3-5 years. Medical management alone can also provide long-term control, but hypertension and hypokalemia may be more difficult to manage. In ferrets, the prognosis is also good, but recurrence is possible if the tumor is not completely excised. Malignant aldosteronomas carry a poorer prognosis, with a higher risk of metastasis. Negative prognostic indicators include severe hypertension at diagnosis, concurrent renal disease, and the presence of metastatic disease. With medical management, blood pressure and potassium levels should be monitored regularly to prevent complications. Overall, the prognosis is favorable if the disease is diagnosed early and treated aggressively.

Follow-up for aldosteronoma includes regular monitoring of blood pressure, serum potassium, and renal function. After surgical adrenalectomy, blood pressure and potassium should be checked at 1, 3, and 6 months postoperatively, then every 6-12 months. If medical management is used, blood pressure and potassium should be monitored every 2-4 weeks until stable, then every 3-6 months. Serial measurements of plasma aldosterone and renin activity may be useful to assess response to therapy. Imaging (ultrasound) should be repeated every 6-12 months to monitor for tumor recurrence or metastasis. In cases of malignant aldosteronoma, more frequent monitoring is recommended. Additionally, cardiac and ocular examinations should be performed periodically to assess for hypertensive complications.

Pearls: 1) Always measure blood pressure in any cat or ferret with unexplained weakness or polyuria/polydipsia. 2) Hypokalemia in a cat with hypertension is highly suggestive of aldosteronoma. 3) The aldosterone-to-renin ratio (ARR) is the most reliable screening test; ensure that ACE inhibitors and spironolactone are discontinued for at least 2 weeks before testing. 4) In ferrets, adrenal disease may present with alopecia, and aldosteronoma should be considered if hypertension or hypokalemia is present. 5) Surgical adrenalectomy is curative for benign tumors; refer to a surgeon experienced in adrenal surgery. Pitfalls: 1) Failing to measure blood pressure in cats with chronic kidney disease, as hypertension may be due to aldosteronoma rather than CKD. 2) Using spironolactone without potassium supplementation can lead to hyperkalemia, especially in patients with renal impairment. 3) Misinterpreting a normal potassium level as ruling out aldosteronoma; some patients may have normokalemia. 4) Not performing abdominal ultrasound in a hypertensive cat with hypokalemia, leading to a missed diagnosis. 5) Overlooking the possibility of a contralateral adrenal gland suppression, leading to hypoadrenocorticism postoperatively.

Current drug protocols for aldosteronoma are based on Plumb's Veterinary Drug Handbook. 1) Spironolactone: In cats and dogs, 1-2 mg/kg PO q12h. In ferrets, 1-2 mg/kg PO q12h. It is a potassium-sparing diuretic and aldosterone antagonist. Contraindicated in hyperkalemia and acute renal failure. Monitor potassium levels. 2) Amlodipine: In cats and dogs, 0.1-0.2 mg/kg PO q24h. In ferrets, 0.1-0.2 mg/kg PO q24h. It is a calcium channel blocker used for hypertension. May cause gingival hyperplasia. 3) Potassium supplementation: Potassium gluconate (e.g., Tumil-K) at 2-4 mEq/kg/day PO divided q12h, or potassium citrate at 40-60 mg/kg PO q12h. Titrate based on serum potassium. 4) Enalapril: 0.5 mg/kg PO q12h in dogs and cats, used as an adjunct for hypertension. 5) For ferrets, melatonin (0.5-1 mg PO q12h) or deslorelin acetate implant (4.7 mg SC) may be used to manage adrenal disease, but they do not directly address aldosterone excess. 6) In cases of congestive heart failure secondary to hypertension, furosemide (1-2 mg/kg IV or PO q8-12h) and pimobendan (0.25 mg/kg PO q12h) may be indicated. Always adjust dosages for renal or hepatic impairment.

Evidence-based literature on aldosteronoma in veterinary medicine is limited but growing. A landmark study by Javadi et al. (2005) described the clinical and pathological features of primary hyperaldosteronism in cats, highlighting the importance of the aldosterone-to-renin ratio for diagnosis. Another study by Ash et al. (2005) reported successful surgical management of aldosteronoma in cats, with a median survival time of 3 years. In ferrets, a study by Rosenthal et al. (1993) documented the association between adrenal tumors and hyperaldosteronism. ACVIM consensus statements on hypertension in dogs and cats (Brown et al., 2007) provide guidelines for blood pressure measurement and management, which are applicable to aldosteronoma. More recent studies have evaluated the use of spironolactone and amlodipine in cats with primary hyperaldosteronism, showing good control of hypertension and hypokalemia. However, there are no large randomized controlled trials, and most evidence is based on case series and expert opinion. Future research should focus on genetic markers and optimal medical protocols.